Puma Biotechnology Inc Total Liabilities
Puma Biotechnology Inc total liabilities. Based on the latest financial reports, Puma Biotechnology Inc (PBYI) has total liabilities worth $85.96 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Puma Biotechnology Inc (PBYI) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Puma Biotechnology Inc (2007–2025)
Total liabilities of Puma Biotechnology Inc from 2007 to 2025. This chart illustrates how Puma Biotechnology Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Puma Biotechnology Inc (PBYI) long-term investment share to see how much of total assets are deployed in long-term investments.
Puma Biotechnology Inc Competitors by Total Liabilities
The table below lists competitors of Puma Biotechnology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Home Invest Belgium - Sifi
BR:HOMI
|
Belgium | €471.46 Million |
|
Smcp SAS
PA:SMCP
|
France | €978.00 Million |
|
Ronshin Group A
SHE:301231
|
China | CN¥134.42 Million |
|
Cedar Development Co Ltd
SHE:002485
|
China | CN¥522.50 Million |
|
Shenzhen Zqgame
SHE:300052
|
China | CN¥366.57 Million |
|
Thonburi Healthcare Grp Pcl
BK:THG
|
Thailand | ฿5.92 Billion |
|
Methode Electronics Inc
NYSE:MEI
|
USA | $628.60 Million |
|
PARKEN Sport & Entertainment
CO:PARKEN
|
Denmark | Dkr2.54 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Puma Biotechnology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PBYI total assets.
Liquidity & Leverage Metrics
Puma Biotechnology Inc Total Liabilities Ratios Explained
Puma Biotechnology Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Puma Biotechnology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Puma Biotechnology Inc (2007–2025)
The table below shows the annual total liabilities of Puma Biotechnology Inc from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $85.96 Million | -29.08% |
| 2024-12-31 | $121.21 Million | -31.55% |
| 2023-12-31 | $177.09 Million | -11.66% |
| 2022-12-31 | $200.45 Million | -12.48% |
| 2021-12-31 | $229.03 Million | -8.45% |
| 2020-12-31 | $250.17 Million | +15.05% |
| 2019-12-31 | $217.44 Million | -3.28% |
| 2018-12-31 | $224.82 Million | +100.33% |
| 2017-12-31 | $112.22 Million | +161.19% |
| 2016-12-31 | $42.97 Million | +26.99% |
| 2015-12-31 | $33.84 Million | -25.98% |
| 2014-12-31 | $45.71 Million | +124.21% |
| 2013-12-31 | $20.39 Million | -10.54% |
| 2012-12-31 | $22.79 Million | +2122.04% |
| 2011-12-31 | $1.03 Million | +45082.03% |
| 2009-12-31 | $2.27K | +0.93% |
| 2008-12-31 | $2.25K | -99.84% |
| 2007-12-31 | $1.41 Million | -- |
About Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined wit… Read more